Please assess the completion status of the following clinical trial:

Trial Title: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female pretreated outpatients between ages 18 and 80 years (inclusive)~* A clinical diagnosis of bilateral blepharospasm (BEB) characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi muscles~* A need for injection of Botulinum toxin (defined by a Jankovic Rating Scale (JRS) severity subscore \>= 2)~* On a stable dose of other medications (if any) used for focal dystonia treatment (e.g. anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the Main Period~* Source documentation of the last two consecutive injection sessions with BOTOX® and a stable satisfactory therapeutic response directly prior to trial entry~* At least 10 weeks must have been passed between the last injection with BOTOX® for BEB and Baseline~Main Exclusion Criteria:~* Atypical variant of BEB caused by inhibition of levator palpebrae muscle~* Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation and/or spinal cord stimulation)~* The previous two injections with BOTOX® with more than 50 Units per eye~* Hypersensitivity to human serum albumin, sucrose, or Botulinum toxin A~* Neuroleptic induced blepharospasm~* Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial~* Treatment with Botulinum toxins for any indication other than BEB within 4 months prior to Baseline and during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- incobotulinumtoxinA (Xeomin) (Type: EXPERIMENTAL): incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).